Declines in HIV incidence among men and women in a South African population-based cohort by Vandormael, Alain et al.
ARTICLE
Declines in HIV incidence among men and women
in a South African population-based cohort
Alain Vandormael 1,2,3,4*, Adam Akullian 5,6, Mark Siedner1,7,8, Tulio de Oliveira4,6,9,
Till Bärnighausen1,3,10 & Frank Tanser1,2,9,11
Over the past decade, there has been a massive scale-up of primary and secondary pre-
vention services to reduce the population-wide incidence of HIV. However, the impact of
these services on HIV incidence has not been demonstrated using a prospectively followed,
population-based cohort from South Africa—the country with the world’s highest rate of new
infections. To quantify HIV incidence trends in a hyperendemic population, we tested a
cohort of 22,239 uninfected participants over 92,877 person-years of observation. We report
a 43% decline in the overall incidence rate between 2012 and 2017, from 4.0 to 2.3 ser-
oconversion events per 100 person-years. Men experienced an earlier and larger incidence
decline than women (59% vs. 37% reduction), which is consistent with male circumcision
scale-up and higher levels of female antiretroviral therapy coverage. Additional efforts are
needed to get more men onto consistent, suppressive treatment so that new HIV infections
can be reduced among women.
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Over the past decade, there has been a massive scale-up oftreatment and prevention services to bring the HIVepidemic under control1. These efforts have led to an
estimated 50% reduction in the number of AIDS-related deaths
over the last 6 years2. However, progress to reduce the HIV
incidence rate (IR) by 75% is off track3, with 1.8 million new
infections occurring in 20174. The Joint United Nations Pro-
gramme on HIV and AIDS (UNAIDS) has recently described the
limited success in reducing new HIV infections, which is
unmatched by the success in reducing AIDS-related deaths, as a
“prevention crisis”5.
There is an urgent need to measure the impact of primary and
secondary prevention services on long-term HIV incidence trends
in southern Africa—the region accounting for one-third of all
new infections4,6. In eastern Africa, estimates of HIV incidence
declines have varied between 40–50% following increased anti-
retroviral therapy (ART) and voluntary medical male circumci-
sion (VMMC) coverage7,8. Nevertheless, reductions in incidence
have not been rigorously demonstrated using a prospectively
followed, population-based cohort from southern Africa, which
has a much higher rate of new HIV infections and has
received substantial domestic and international investment to
achieve epidemic control1,4. Attention is focused on the country
with the world’s largest treatment and prevention program: South
Africa9.
One major challenge in reliably measuring HIV incidence
trends in southern Africa (as well as the broader African region)
has been the limited number of population-based cohort studies.
Previous estimates of incidence declines in the region have been
derived from mathematical models or cross-sectional assay-based
studies5,10,11. However, mathematical models rely on strong
assumptions and non-representative data (e.g., women attending
antenatal clinics), while cross-sectional studies do not track the
same participants over time12,13. The repeated testing of a com-
plete population of participants until HIV seroconversion is
generally recognized as the gold-standard approach for measur-
ing trends in the incidence of infection14.
In our previous work, we demonstrated a clear relationship
between ART coverage in the surrounding local community and
individual risk of HIV acquisition in a hyperendemic South
African setting15. However, we have yet to report on long-term,
population-wide HIV incidence trends and their relation to the
scale-up of primary and secondary prevention services. Speciﬁ-
cally, we use one of the world’s largest population-based HIV
cohorts, with over 90,000 person-years of observation, to quantify
sex-speciﬁc trends in HIV incidence following changes in ART
coverage, prevalence of detectable viremia, condom use,
and male circumcision. We leverage several differing methodol-
ogies to validate our estimates and ensure the robustness of our
ﬁndings.
We report that the overall incidence of HIV infection between
2012 and 2017 declined by 43%. Our key ﬁnding is that men
experienced earlier and larger declines than women, plausibly due
to a sex differential in the uptake of primary and secondary pre-
vention services. Speciﬁcally, we show that male incidence declined
by 59%, from 2.5 to 1.0 seroconversion events per 100 person-years,
which is consistent with VMMC scale-up in 2009 and female ART
coverage surpassing 35% in 2012. We also report a 37% reduction
in the female incidence between 2014 and 2017, from 4.9 to
3.1 seroconversion events per 100 person-years, which occurred
after male ART coverage reached 35%. Thus, although HIV pre-
vention efforts should continue to focus on both men and women,
there is an urgent need to get more men onto consistent, sup-
pressive ART so that new HIV infections can be further reduced
among women.
Results
Population-based HIV testing platform. The Africa Health
Research Institute (AHRI) runs a population-based HIV testing
platform in the Hlabisa sub-district of KwaZulu-Natal16.
Approximately 90,000 persons reside in 11,000 households, which
are mostly scattered across the 438 km2 study area. As is typical
for a rural South African setting, there are several informal peri-
urban settlements and a single urban township. The majority of
the residents are Zulu-speaking (black) Africans.
Two to three times yearly, trained ﬁeld workers visit all
households in the study area to interview a key resident
informant. The key informant is often the household head or
the most senior household member; if not available, other suitable
household members are selected. The key informant provides
information on the physical attributes of the household; the
resident members and their relationship to one another; members
who join, leave, or die; and the migration patterns of members,
including place of origin and destination. For each death in the
household, the key informant completes a detailed verbal autopsy
questionnaire administered by the ﬁeld-worker. To undertake
annual HIV testing, ﬁeld workers obtain written consent from
eligible participants who are present, mentally able, and older
than 15 years of age. Participants ﬁrst answer questions about
their sexual health, relationship history, use of condoms with a
sexual partner, and circumcision status (men only between 2009
and 2016). The ﬁeld workers then extract dried blood spot (DBS)
samples for HIV and viral load testing17,18.
Prevention services at the 17 public healthcare clinics in or
adjacent to the study area have included HIV testing and
counseling, condom distribution, ART availability, and voluntary
medical circumcision for men. The local VMMC program was
started in 2009 and the national HIV testing and counseling
services were expanded in 2010. ART became freely available
nationwide in 2004, with a CD4+ T-cell count eligibility criteria
of <200 cells/μL. In 2010, eligibility was extended to pregnant
woman with CD4+ T-cell counts <350 cells/μL and to patients
with active tuberculosis19. All patients with CD4+ T-cell counts
<350 cells/μL became eligible for ART in 2011. In 2015, ART was
made available to HIV-positive pregnant women regardless of
CD4+ T-cell count and to all late adolescents and adults with
CD4+ T-cell counts <500 cells/μL. In 2016, all HIV-positive
persons became eligible for ART20.
We linked ~60% of all HIV-positive participants to the 17
public healthcare clinics in the study area. From these clinics we
obtained records on ART initiation and clinic visit dates. The
remaining ~40% of HIV-positive participants had either never
been initiated on ART or initiated ART at other clinics outside
this setting.
Survey participation. Table 1 shows the participation rates in the
HIV survey. On average, 92% (range: 84–97%) of the enumerated
participants were eligible for an HIV test, 85% (range: 76–93%) of
the eligible participants were contacted at the household visit, and
41% (range: 34–52%) of the contacted participants tested for
HIV. Supplementary Fig. 1 shows that the HIV testing rate did
not differ substantially by age or sex over the observation period.
Because of the annual surveys, the cumulative percentage of
participants that had at least one HIV test increased from 60% in
2005 to 68% in 2010 and to 80% in 2017. Overall, a total of 53,167
participants tested for HIV over 158,369 person-visits. Table 1
also shows the number of eligible HIV-negative participants by
year (column 9) and the number of these participants that had a
repeat HIV test (column 10). On average, 76% (range: 69–87%) of
the eligible HIV-negative participants entered into the HIV
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cohort (column 11). The median length of the censoring interval
was 3 years.
Unadjusted HIV incidence rates and rate ratios. Of the parti-
cipants that tested for HIV, 22,239 had a negative test result
followed by at least one valid test result. Of these repeat testers,
12,609 (57%) were women and 9630 (43%) were men. The
median (interquartile range age was 22 (19–31) and 24 (19–37)
years for men and women, respectively. We observed 770 ser-
oconversion events per 38,071 person-years of follow-up among
men and 2410 seroconversion events per 54,806 person-years of
follow-up among women.
Tables 2 and 3 show the HIV events, person-years, unadjusted
IRs, and unadjusted IR ratios (IRRs) by year. Declines in HIV
incidence occurred once opposite-sex ART coverage surpassed
35% (Model 1) and ART eligibility criteria were removed in 2016
(Model 2). Between 2012 and 2017, the HIV IR (95% conﬁdence
interval [CI]) among men declined by 59%, from 2.49 (1.83–3.37)
to 1.01 (0.58–1.76) seroconversion events per 100 person-years
(see Fig. 1 and Table 2). HIV incidence was higher among women
and relatively ﬂat between 2005 and 2013, at around 4.3 ser-
oconversion events per 100 person-years. Thereafter, between
2014 and 2017, the female HIV incidence declined by 37%, from
4.89 (4.09–5.84) to 3.06 (2.38–3.94) seroconversion events per
100 person-years (see Fig. 1 and Table 3). Between 2012 and
2017, the overall HIV IR among men and women declined from
3.94 (3.37–4.60) to 2.25 (1.79–2.83) events per 100 person-years,
a 43% reduction (see Supplementary Table 1).
Age-speciﬁc HIV incidence and HIV prevalence. Figure 2 shows
the HIV incidence and HIV prevalence for the 15–49, 15–29, and
30–54 years age groups by sex. Between 2005 and 2017, the HIV
prevalence for the 15–54-year age group increased from 14% to
20% among men and from 25% to 41% among women. HIV
incidence was highest among women aged 15–29 years, which
decreased markedly between 2014 and 2017. HIV prevalence was
extremely high among women aged 30–49 years, which increased
from 32% in 2005 to 59% in 2017. The female HIV incidence in
this older age group did not decline until the last year of the
observation period.
ART coverage and prevalence of detectable viremia. Supple-
mentary Tables 2 and 3 show the number and percentage of
HIV-positive men and women on ART, respectively. Among
HIV-positive women, ART coverage increased from 2.1% in 2005
Table 1 Summary of testing participation in the HIV survey and HIV incidence cohort.
HIV surveya HIV incidence Ccohortb
Eligible/enumeratedc Contact/eligibled Tested/contactede Ever
testf
Eligibleg Repeat-testersh
Year No./total no. % No./total no. % No./total no. % % No. No. %
2005 25,203/
26,477
(95.2) 22,105/
25,203
(87.7) 9422/22,105 (42.6) 59.8 11,396 9936 (87.2)
2006 23,536/
26,209
(89.8) 21,538/
23,536
(91.5) 8643/21,538 (40.1) 61.8 13,973 11,522 (82.5)
2007 28,364/
32,844
(86.4) 25,689/
28,364
(90.6) 9957/25,689 (38.8) 60.4 16,064 12,898 (80.3)
2008 31,020/
36,228
(85.6) 28,859/
31,020
(93.0) 10,032/
28,859
(34.8) 61.5 17,958 14,163 (78.9)
2009 27,077/
32,072
(84.4) 24,795/
27,077
(91.6) 8858/
24,795
(35.7) 66.2 19,074 14,816 (77.7)
2010 32,173/
34,968
(92.0) 26,520/
32,173
(82.4) 11,228/
26,520
(42.3) 68.0 21,483 16,367 (76.2)
2011 32,127/
32,978
(97.4) 25,586/
32,127
(79.6) 10,385/
25,586
(40.6) 70.7 23,052 17,242 (74.8)
2012 30,506/
32,327
(94.4) 23,145/
30,506
(75.9) 7916/23,145 (34.2) 69.6 24,519 18,199 (74.2)
2013 30,768/
32,964
(93.3) 24,840/
30,768
(80.7) 9912/24,840 (39.9) 72.5 26,500 19,482 (73.5)
2014 31,225/
33,013
(94.6) 24,471/
31,225
(78.4) 9541/24,471 (39.0) 74.1 28,027 20,532 (73.3)
2015 30,509/
32,211
(94.7) 27,085/
30,509
(88.8) 13,096/
27,085
(48.4) 78.0 30,143 21,832 (72.4)
2016 32,502/
34,044
(95.5) 28,239/
32,502
(86.9) 14,737/
28,239
(52.2) 80.4 32,481 22,943 (70.6)
2017 31,687/
34,542
(91.7) 26,240/
31,687
(82.8) 11,430/
26,240
(43.6) 80.5 33,837 23,445 (69.3)
Average (91.9) (85.4) (40.9) (76.2)
aTrained ﬁeld workers visit all households in the surveillance area on an annual basis to take dried blood spots for HIV testing. Field workers also record data on whether participants were contacted and
tested at the household visit
bParticipants entered into the HIV incidence cohort if they had an earliest HIV-negative test result followed by at least one valid HIV test result
cEnumerated refers to all individuals living in the household, as identiﬁed by a key household informant at the time of the ﬁeld-worker visit. Eligibility was deﬁned as being >15 years of age, mentally able,
and a resident of the household. The column shows the number and percentage of enumerated individuals that were eligible for an HIV test
dShows the number and percentage of eligible participants that were successfully contacted (i.e., that were present in the household) at the time of the ﬁeld-worker visit
eShows the number and percentage of contacted participants that were tested for HIV
fShows the cumulative proportion of participants that tested at least once for HIV since the start of HIV testing in 2003
gShows the cumulative number of HIV-negative participants since 2003 that were eligible for entry into the HIV incidence cohort in 2005
hShows the number of eligible HIV-negative participants that had a repeat-test, entered the HIV cohort, and contributed person-time to the incidence analysis. For example, if a participant had a ﬁrst and
last HIV-negative test in 2006 and 2010, then he she is included in the year 2006, 2007, 2008, 2009, and 2010, irrespective of the number of missed tests during this exposure time. The last column
gives the annual percentage of eligible HIV-negative participants that entered the HIV cohort
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Table 2 Incidence rates (IRs, unadjusted) and incidence rate ratios (IRRs, unadjusted and adjusted) for men (N= 9630) by
female ART coverage, ART scale-up period, and year.
Events Person-years Inc rate (95% CI) Unadj. IRR (95% CI) P-value Adj. IRR (95% CI)d P-value
Model 1: By female ART coveragea
0–9% 149 6809 2.20 (1.81–2.68) Ref. – Ref. –
10–24% 339 14,175 2.40 (2.12–2.71) 1.09 (0.85–1.39) 0.495 0.72 (0.58–0.89) <0.01
25–34% 74 3221 2.30 (1.70–3.11) 1.05 (0.73–1.51) 0.805 0.64 (0.46–0.89) <0.01
35–55% 294 16,669 1.76 (1.55–2.01) 0.80 (0.63–1.02) 0.068 0.52 (0.40–0.68) <0.01
Model 2: By ART scale-up periodb
2005–2010 489 20,984 2.33 (2.12–2.57) Ref. – Ref. –
2011–2015 315 15,308 2.06 (1.82–2.33) 0.88 (0.75–1.04) 0.147 0.75 (0.62–0.90) <0.01
2016–2017 52 4582 1.15 (0.82–1.60) 0.49 (0.34–0.70) <0.01 0.52 (0.38–0.72) <0.01
Model 3: By yearc
2005 69 3239 2.14 (1.57–2.93) 0.86 (0.56–1.33) 0.504 1.50 (1.04–2.16) 0.028
2006 80 3569 2.24 (1.69–2.96) 0.90 (0.59–1.36) 0.621 1.46 (1.02–2.08) 0.038
2007 84 3634 2.30 (1.74–3.05) 0.93 (0.61–1.42) 0.724 1.06 (0.74–1.52) 0.755
2008 86 3679 2.35 (1.78–3.09) 0.94 (0.63–1.42) 0.783 0.98 (0.68–1.41) 0.910
2009 85 3483 2.45 (1.85–3.24) 0.99 (0.65–1.50) 0.947 1.10 (0.78–1.55) 0.599
2010 83 3377 2.45 (1.85–3.25) 0.99 (0.65–1.50) 0.952 1.06 (0.76–1.48) 0.732
2011 74 3221 2.30 (1.70–3.11) 0.93 (0.58–1.47) 0.744 0.92 (0.65–1.30) 0.621
2012 75 3039 2.49 (1.83–3.37) Ref. – Ref. –
2013 67 3033 2.22 (1.64–3.01) 0.89 (0.57–1.39) 0.620 0.92 (0.65–1.30) 0.621
2014 56 3046 1.83 (1.29–2.59) 0.73 (0.45–1.19) 0.210 0.65 (0.44–0.96) 0.029
2015 41 2967 1.39 (0.94–2.07) 0.56 (0.34–0.93) 0.025 0.65 (0.44–0.95) 0.027
2016 32 2602 1.24 (0.79–1.95) 0.50 (0.29–0.87) 0.014 0.70 (0.47–1.04) 0.074
2017 20 1979 1.01 (0.58–1.76) 0.41 (0.22–0.76) <0.01 0.39 (0.23–0.67) <0.01
HIV events, person-years, unadjusted IRs, and unadjusted adjusted IRRs are averages over 300 datasets generated by imputing a single random infection date within the censoring interval. Rubin’s rules
were used to calculate 95% conﬁdence intervals
aOpposite-sex ART coverage used because of the generalized, heterosexual HIV epidemic in South Africa, with 0–9% as the reference category
bTime intervals were deﬁned by changes in national criteria for ART eligibility, with 2005–2010 as the reference period
cTime intervals were deﬁned by year, with 2012 as the reference year
dEstimates adjusted for age, self-reported condom use, circumcision and marital status, household assets index, cumulative time spent outside surveillance area, and opposite-sex HIV prevalence in the
surrounding community (see Supplementary Table 4 for full results)
Table 3 Incidence rates (IRs, unadjusted) and incidence rate ratios (IRRs, unadjusted and adjusted) for women (N= 12,609) by
male ART coverage, ART scale-up period, and year.
Events Person-years Inc rate (95% CI) Unadj. IRR (95% CI) P-value Adj. IRR (95% CI)d P-value
Model 1: By male ART coveragea
0–9% 642 14,653 4.38 (4.00–4.79) Ref. – Ref. –
10–24% 674 14,549 4.63 (4.24–5.07) 1.06 (0.92–1.21) 0.422 0.99 (0.89–1.11) 0.891
25–34% 847 17,570 4.82 (4.47–5.21) 1.10 (0.98–1.24) 0.114 0.87 (0.77–0.97) 0.016
35–55% 416 11,014 3.78 (3.38–4.23) 0.86 (0.75–1.00) 0.043 0.68 (0.59–0.78) <0.01
Model 2: By ART scale-up periodb
2005–2010 1,316 29,203 4.51 (4.25–4.78) Ref. – Ref. –
2011–2015 1,030 21,796 4.73 (4.42–5.05) 1.05 (0.96–1.15) 0.317 0.85 (0.77–0.93) <0.01
2016–2017 234 6789 3.45 (2.95–4.02) 0.76 (0.65–0.90) <0.01 0.63 (0.55–0.74) <0.01
Model 3: By yearc
2005 186 4567 4.08 (3.40–4.90) 0.84 (0.65–1.08) 0.166 1.11 (0.90–1.37) 0.339
2006 223 5008 4.45 (3.77–5.27) 0.91 (0.71–1.17) 0.465 1.16 (0.95–1.42) 0.157
2007 231 5078 4.56 (3.86–5.39) 0.93 (0.73–1.19) 0.585 1.18 (0.97–1.44) 0.097
2008 231 5050 4.58 (3.89–5.40) 0.94 (0.74–1.19) 0.604 1.13 (0.92–1.38) 0.234
2009 220 4818 4.58 (3.85–5.44) 0.94 (0.73–1.20) 0.604 1.14 (0.94–1.39) 0.176
2010 221 4681 4.72 (3.98–5.61) 0.97 (0.75–1.25) 0.795 1.15 (0.94–1.40) 0.169
2011 209 4566 4.59 (3.85–5.47) 0.94 (0.73–1.21) 0.624 0.97 (0.79–1.20) 0.803
2012 214 4319 4.95 (4.14–5.92) 1.01 (0.78–1.31) 0.920 1.02 (0.83–1.25) 0.846
2013 211 4354 4.85 (4.05–5.81) 0.99 (0.76–1.30) 0.961 1.00 (0.82–1.21) 0.968
2014 211 4329 4.89 (4.09–5.84) Ref. – Ref. –
2015 182 4225 4.31 (3.58–5.20) 0.88 (0.67–1.16) 0.368 0.86 (0.71–1.06) 0.164
2016 141 3783 3.74 (3.04–4.61) 0.77 (0.58–1.02) 0.064 0.78 (0.63–0.97) 0.026
2017 92 3005 3.06 (2.38–3.94) 0.63 (0.46–0.86) <0.01 0.65 (0.51–0.83) <0.01
HIV events, person-years, unadjusted IRs, and unadjusted adjusted IRRs are averages over 300 datasets generated by imputing a single random infection date within the censoring interval. Rubin’s rules
were used to calculate 95% conﬁdence intervals
aOpposite-sex ART coverage used because of the generalized, heterosexual HIV epidemic in South Africa, with 0–9% as the reference category
bTime intervals were deﬁned by changes in national criteria for ART eligibility, with 2005–2010 as the reference period
cTime intervals were deﬁned by year, with 2012 as the reference year
dEstimates adjusted for age, self-reported condom use, circumcision and marital status, household assets index, cumulative time spent outside surveillance area, and opposite-sex HIV prevalence in the
surrounding community (see Supplementary Table 5 for full results)
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to 24.6% in 2010, and to 50.6% in 2017. ART coverage was lower
among HIV-positive men, which increased from 1.5% in 2005 to
21.4% in 2010, and then to 38.4% in 2017. As reported else-
where21, the population prevalence of detectable viremia among
women declined from 72.8% in 2011 to 62.0% in 2013 and 55.3%
in 2014. Among men, it declined from 77.8% in 2011 to 70.4% in
2013 and 67.2% in 2014 (see Fig. 3).
Condom use and circumcision status. Supplementary Tables 2
and 3 also show the number and percentage of men and women
reporting condom use in relationships. As reported by women,
condom use among male partners increased from 33.8% in 2005
to 60.5% in 2011, and averaged around 64% thereafter. Among
men, self-reported condom use was stable between 2011 and
2017, at around 70%, having risen from 43.6% in 2005 to 71.6%
in 2011. Supplementary Table 2 shows that self-reported cir-
cumcision coverage among men in the study area increased from
3.0% to 32.9% between 2009 and 2016. Among circumcised men,
the HIV IR declined by 59%, from 1.24 (0.57–2.69) to 0.5
(0.16–1.57) events per 100 person-years between 2012 and 2016
(Fig. 4). During the same period, the IR among uncircumcised
men declined from 3.01 (2.16–4.18) to 1.73 (1.01–2.97) events per
100 person-years—a comparatively lower reduction of 42%.
Adjusted HIV incidence rate ratios. We show the adjusted IRRs
by ART coverage category, ART eligibility period, and year in
Tables 2 and 3, and the full results in Supplementary Tables 4 and
5. For Model 1, declines in the adjusted male and female IRRs
were associated with increased opposite-sex ART coverage,
holding HIV prevalence and other key risk factors for HIV
acquisition constant. Declines in the adjusted male and female
IRRs were also signiﬁcantly associated with more inclusive ART
eligibility criteria, as shown in Model 2. Model 3 conﬁrms
declines in the adjusted male and female IRRs after 2012 and
2014, respectively.
Results show that men in the 25–29-year age group and women
in the 20–24-year age group were at the greatest risk of HIV
infection, when compared with 15–19-year-olds (Supplementary
Tables 4 and 5). Circumcised men had a signiﬁcantly lower
adjusted IRR when compared with uncircumcised men (Supple-
mentary Table 4). Compared with women, uncircumcised and
circumcised men had a signiﬁcantly lower adjusted IRR
(Supplementary Table 6). Greater time spent outside of the study
area and higher levels of HIV prevalence were associated with an
increased risk of HIV acquisition across the multivariate models
(Supplementary Tables 4–6).
Trends in measures from 2010 to 2017. In Fig. 3 we present
trends in the sex-speciﬁc HIV incidence, self-reported condom
use, self-reported male circumcision, opposite-sex ART coverage,
and opposite-sex prevalence of detectable viremia. The left panel
shows the decline in male incidence coincided with increased
circumcision coverage, female ART coverage surpassing 35% after
2012, and a decline in the female prevalence of detectable viremia.
The right panel shows the female incidence declined once male
ART coverage surpassed 35% after 2014, with a lower reduction
in the male prevalence of detectable viremia when compared with
women. Condom use among men and women remained
unchanged between 2012 and 2017.
Discussion
Using a prospectively followed, population-based cohort from a
hyperendemic South African setting, we demonstrate a 43%
decline in the incidence of HIV infection between 2012 and 2017.
Men experienced an earlier and larger decline in incidence, which
we attribute to the introduction of a local VMMC program in
2009, the scale-up of national testing and counseling services in
2010, and female ART coverage surpassing 35% in 2012. Among
women, the comparatively lower decline in incidence began after
2014, once male ART coverage reached 35%. The unequal
declines in HIV incidence are broadly consistent with a sex dif-
ferential in the uptake of primary and secondary prevention
services in the study area22.
Our ﬁndings are biologically plausible: we would expect to
observe earlier and larger population-level reductions in the male
HIV IR following earlier VMMC scale-up and higher levels of
ART coverage among women. VMMC is beneﬁcial for men and
has been associated with a reduced risk of male HIV acquisition
in sub-Saharan African settings23–25. In 2009, a local VMMC
program was introduced into the study area and by 2016 self-
reported circumcision coverage had reached 33%. Our results
conﬁrm the preventative beneﬁts of circumcision for men, who
had a lower incidence of infection when compared with uncir-
cumcised men. Uncircumcised male participants also had a
markedly lower rate of new HIV infections than women, which is
likely to have contributed to the earlier and larger declines in the
overall incidence among men.
Men also likely beneﬁted from higher female engagement with
the healthcare system. At least partly due to perinatal HIV
screening and treatment programs, women are more likely than
men to test for HIV, initiate ART early, and achieve long-term
undetectable viremia26–28. Given the generalized, heterosexual
HIV epidemic in sub-Saharan Africa, this means that men will
have a comparatively lower risk of meeting female sexual partners
with detectable HIV viremia and acquiring HIV (on average and
under the assumption of a well-mixed population sexual network)
21,29,30. We have previously found that the prevalence of detect-
able viremia, when combined with the underlying spatial varia-
tion in the proportion of the population infected (HIV
prevalence), was strongly associated with future HIV infections.
Speciﬁcally, every 1% increase in the overall proportion of the
population having detectable viremia was independently
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Fig. 1 HIV incidence rates with 95% conﬁdence intervals (CIs). The ﬁgure
shows that male and female HIV incidence declined after 2012 and 2014,
respectively, with an overall decline of 43% between 2012 and 2017.
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associated with a 6.3% increase in the prospective risk of HIV
acquisition29. We hypothesize that higher levels of ART coverage
and hence lower population levels of detectable viremia among
women were two important factors that contributed to larger and
earlier declines in HIV incidence among men.
Our ﬁnding of a large HIV incidence decline is consistent with
other regions in sub-Saharan Africa. Recently, an ongoing cohort
study from the Rakai district in Uganda estimated a 42% decline
in the overall HIV IR between 2012 and 2016. This decline was
attributed to increased ART coverage, VMMC scale-up, and
possibly reduced sexual activity in late adolescence7. In western
Kenya, the scale-up of VMMC services, and to a lesser extent
increased ART coverage, was associated with a 50% reduction in
the HIV IR between 2011 and 20168. Representative cross-
sectional studies from eSwatini (Swaziland) and South Africa
have recently reported similar reductions in HIV incidence over
the last six years31,32. Consistent with these results, we show for
the ﬁrst time, in a southern African setting, signiﬁcant declines in
8 60
50
40
30
20
10
0
60
50
40
30
20
10
0
60
50
40
30
20
10
0
60
50
40
30
20
10
0
60
50
40
30
20
10
0
60
50
40
30
20
10
0
6
4
2
0
2005 2007 2009 2011 2013 2015 2017
2005 2007 2009 2011 2013 2015 2017
2005 2007 2009 2011
Year Year
2013 2015 2017
2005 2007 2009 2011 2013 2015 2017
2005 2007 2009 2011 2013 2015 2017
2005 2007 2009 2011 2013 2015 2017
8
6
4
2
0
8
6
4
2
0
8
6
4
2
0
8
6
4
2
0
8
6
4
2
0
H
IV
 in
ci
de
nc
e/
10
0 
p-
ye
ar
s
H
IV
 in
ci
de
nc
e/
10
0 
p-
ye
ar
s
H
IV
 in
ci
de
nc
e/
10
0 
p-
ye
ar
s
HIV incidence
Women: 15–49 years
Women: 15–29 years
Women: 30–49 years
Men: 15–54 years
Men: 15–29 years
Men: 30–54 years
HIV prevalence
H
IV
 p
re
va
le
nc
e 
(%
)
H
IV
 p
re
va
le
nc
e 
(%
)
H
IV
 p
re
va
le
nc
e 
(%
)
Fig. 2 HIV incidence rates (with 95% CIs) and HIV prevalence by sex and age. The ﬁgure shows that HIV incidence was highest among younger
participants (15–29 years) and HIV prevalence was highest among older women (30–49 years). The largest declines in HIV incidence occurred among
younger women, whereas HIV incidence was relatively ﬂat among older women.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13473-y
6 NATURE COMMUNICATIONS |         (2019) 10:5482 | https://doi.org/10.1038/s41467-019-13473-y | www.nature.com/naturecommunications
the HIV IR using data from a prospectively followed, population-
based cohort study.
The strength of our study is that we followed a cohort of 22,239
uninfected men and women to identify new HIV infections over
time, which is the gold-standard approach for IR estimation14.
We collected detailed demographic data on age, sex, relationship
status, migration history, condom use, and household socio-
economic status, and calculated the HIV prevalence of the par-
ticipant’s surrounding community. To determine ART status, we
linked HIV-positive participants to their clinic records at public
healthcare facilities in or adjacent to the study area. Further, we
obtained viral load measurements from all HIV-positive blood
samples in 2011, 2013, and 2014 to quantify the population
prevalence of detectable viremia. We therefore had a unique
opportunity to measure trends in the incidence of HIV infection
while adjusting for well-known covariates of HIV infection risk.
We undertook several sensitivity analyses to conﬁrm the
robustness of our ﬁndings. To be sure that our results were not
partially explained by model selection, we obtained unadjusted
IRRs by ART coverage (Model 1), ART scale-up period (Model
2), and year (Model 3). Results show similarities between the
unadjusted IRRs (Tables 2 and 3) and adjusted IRRs (Supple-
mentary Tables 4 and 5). We note that the unadjusted IRRs
declined once ART coverage surpassed 35%, suggesting that
treatment uptake had to reach a population threshold before
reductions in HIV incidence could be observed. After adjusting
for HIV prevalence and other well-established risk factors, we
found that increased ART coverage was associated with steady
declines in the HIV acquisition risk. In earlier analyses, we
demonstrated that reductions in the HIV acquisition risk were
associated with increased ART coverage at the community,
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Fig. 4 Age-adjusted HIV incidence rates for men who reported being
uncircumcised (N= 5134) and circumcised (N= 2306). Due to a small
number of recorded seroconversions between 2009 and 2011, the
incidence rate for circumcised men is plotted from 2012 to 2016. The ﬁgure
shows that uncircumcised men had a lower incidence of HIV infection, and
that declines in HIV incidence occurred after 2012 for both uncircumcised
and circumcised men.
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household, and serodiscordant couple levels, holding HIV pre-
valence and other well-established risk factors constant15,33,34.
Given the correspondence between the unadjusted and adjusted
IRRs, and between our results and previous research, it is unlikely
that the observed declines in HIV incidence could be explained by
model selection.
We further assessed whether missed test dates could have
biased our HIV IR results. To estimate the IR, we identiﬁed
uninfected participants with an earliest negative test result fol-
lowed by at least one test result. We therefore considered (1) the
percentage of eligible HIV-negative participants that entered into
the HIV cohort and (2) the average length of the censoring
interval, deﬁned as the time between the latest HIV-negative and
earliest HIV-positive test dates. First, we show that on average
76% of HIV-negative participants entered into the HIV cohort,
which is a relatively high inclusion rate for a prospective
population-based cohort study. Second, we restricted our analysis
to repeat testers who missed no more than two consecutive test
dates within the censoring interval. Our results show similar IRs
for the restricted and full cohort of repeat testers (Supplementary
Table 7). This is because the single random-point method, when
coupled with standard multiple imputation procedures, produces
robust IR estimates—even with annual testing rates as low as 40%
or average censored intervals as wide as four years. We have
demonstrated this result in recent work35. Importantly, we also
show that the demographic composition (age and sex) of the
HIV-negative testers and the HIV cohort remained stable
throughout the observation period (Supplementary Figs. 2 and 3).
Finally, we also included inverse probability weighting in the
regression models to mitigate the effect of participant selection,
non-testing, and dropout. These sensitivity analyses, together
with the single random-point approach for IR estimation,
strongly support the robustness of our study ﬁndings.
One limitation of our study is that social desirability bias may
have inﬂuenced self-reported circumcision status and condom
use. However, it is not clear whether this bias could explain large
increases in circumcision while condom use remained relatively
ﬂat from 2012 onward. Another potential limitation is that ~40%
of all HIV-positive participants were not linked to their ART
records at public healthcare facilities in or adjacent to the study
area. A large proportion of these patients would be ART naïve,
but some may have initiated ART at other clinics outside this
setting, resulting in an underestimate of ART coverage. However,
underestimated ART coverage would bias our Model 1 results
toward the null hypothesis (i.e., no change in the HIV IR), as we
show that increased ART is associated with a reduction in HIV
acquisition risk. Further, the reductions in HIV incidence by ART
coverage are also consistent with reductions in HIV incidence by
ART scale-up period (Model 2) and by year (Model 3). Given
similar ﬁndings from other regions in sub-Saharan Africa, it is
likely that the observed declines in HIV incidence are related to
the scale-up of ART and other prevention services from 2009
onward.
In summary, we provide robust evidence of HIV incidence
declines among men and women living in a rural and hyperen-
demic South African community. Our results show that the
decline in HIV incidence was larger among men and occurred
earlier, which is consistent with the introduction of a local
VMMC program in 2009 and female ART coverage surpassing
35% in 201222. Declines in the HIV incidence among women
lagged behind men by 2 years and began to decline once male
ART coverage reached 35% in 2014. Overall, HIV incidence
remains high, with women experiencing a higher risk of HIV
acquisition relative to men. We did not observe increases in
condom use between 2012 and 2017. Additional efforts are nee-
ded to increase condom uptake, improve male engagement with
the healthcare system, and ensure the scale-up of primary pre-
vention services (such as pre-exposure prophylaxis) to bring the
HIV epidemic under control by 2030.
Methods
HIV and viral load testing. DBS samples were extracted by ﬁeld workers
according to the UNAIDS and WHO Guidelines for Using HIV Testing Tech-
nologies in Surveillance17. The DBS samples were transported to the AHRI
laboratory in Durban where HIV status was determined by antibody testing with a
broad-based HIV-1/HIV-2 ELISA (Vironostika HIV-1 Microelisa System: Bio-
mérieux, Durham, NC, USA) followed by a second ELISA (Wellcozyme HIV-1+ 2
GACELISA: Murex Diagnostics Benelux B.V., Breukelen, Netherlands). The AHRI
laboratory has used the same HIV testing algorithm since 2005.
From the HIV surveys of 2011, 2013, and 2014, we obtained viral load
measurements from all the HIV-positive DBS samples21. Nucleic acid was
extracted from the DBS samples with NucliSENS EasyMag (Bordeaux, France) and
a Generic HIV Charge Virale (Biocentric, Bandol, France) test was used to quantify
the viral load levels. The quantiﬁcation method has a lower detection limit of 1550
copies/mL18, which we deﬁned as the threshold for detectable viremia.
Statistical analysis. We measured trends in the incidence of HIV infection using a
prospectively followed cohort of repeat testers. To be included in the incidence
cohort, participants had to have an HIV-negative test result followed by at least one
valid HIV test result14. We identiﬁed all repeat testers who converted from an HIV-
negative to an HIV-positive result during the observation period. Assuming a
uniform distribution, we imputed a single random infection date between the latest
HIV-negative and earliest HIV-positive dates (the censoring interval). We then
right censored the data at the latest HIV-negative date (if uninfected) or at the
imputed date (if infected). The rationale for the single random-point method is
provided elsewhere35. We calculated the IRs per 100 person-years and estimated
the IR ratios with Poisson regression models. To quantify the uncertainty of our
imputation procedure, we generated 300 imputed datasets and used Rubin’s rules
to obtain the estimates and 95% CIs36.
We calculated trends in the HIV IR separately for men aged 15–54 years and
women aged 15–49 years between 2005 and 2017. These age-speciﬁc ranges were
used to ensure consistency with previous AHRI analyses15,33,37. We also identiﬁed
pre-circumcision exposure time for men who never reported being circumcised
and post-circumcision exposure time for men who reported being circumcised. We
plotted trends in the HIV IR for uncircumcised men between 2009 and 2016.
Because of the small number of seroconversions recorded between 2009 and 2011,
we plotted the HIV IR for circumcised men between 2012 and 2016.
We calculated the unadjusted IRs and unadjusted IRRs by ART coverage
(Model 1), ART scale-up period (Model 2), and year (Model 3). For Model 1, we
deﬁned ART coverage categories of 0–9% (reference), 10–24%, 25–34%, and
35–55%. For Model 2, we selected the time intervals 2005–2010 (reference),
2011–2015, and 2016–2017 based on changes to national ART eligibility criteria.
For Model 3, we selected 2012 and 2014 (based on peak HIV incidence) as the
reference years for men and women, respectively.
To address potential sources of confounding, we obtained adjusted IRRs using
Poisson regression models. Based on previous research undertaken in the AHRI
study area, we included age33, condom use38, marital status39, male circumcision
status39, household socio-economic status (in tertiles)40, cumulative time spent
outside the study area37,41, and the HIV prevalence of the participant’s
surrounding community29. We ran the analyses separately for men and women,
with opposite-sex ART coverage and opposite-sex HIV prevalence covariates, and
excluded male circumcision status from the female-only models.
To adjust for participant selection and dropout, we included inverse probability
of survey weights in the multivariable Poisson regression models42. Following the
approach of another study7, we used a logistic regression model to predict the
probability of a follow-up test visit given a previous test visit, adjusting for age, HIV
prevalence, and time spent outside the study area. We used the same model to
predict the probability of dropout. After multiplying the follow-up and dropout
weights, we included the resultant weight in the multivariable model.
We calculated ART coverage as the percentage of HIV-positive participants on
treatment, VMMC coverage as the percentage of male participants that reported
being circumcised, and the population prevalence of detectable viremia as the
percentage of HIV-positive participants with detectable viral loads. For men and
women, we plotted trends in self-reported condom use, self-reported circumcision
coverage (men only), opposite-sex ART coverage, and opposite-sex prevalence of
detectable viremia. We undertook all analyses in R version 3.6.1.
Ethics Approval. Written informed consent was obtained from all participants
prior to the household interview and the extraction of DBS for HIV and viral load
testing. Ethics approval for data collection and use was obtained from the bio-
medical and ethics committee (BREC) of the University of KwaZulu-Natal (Dur-
ban, South Africa), BREC approval number BE290/16.
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Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All relevant data supporting the key ﬁndings of this study are available within the article
and its Supplementary Information ﬁles. The datasets used for the analysis presented in
this study are available from the Africa Health Research Institute (AHRI) data repository
https://data.africacentre.ac.za/index.php/auth/login/?destination=. To access the licensed
datasets, the applicant must agree to the terms and conditions of use by completing an
Application for Access to a Licensed Dataset. This request will be reviewed by the AHRI
Data Release Committee, who may decide to approve the request, to deny access to the
data, or to request additional information from the applicant.
Code availability
The R code used to generate the results is available from the corresponding author upon
request.
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